Shares of Agenus Inc (NASDAQ:AGEN) dropped 6.9% on Tuesday . The stock traded as low as $2.29 and last traded at $2.31. Approximately 665,735 shares were traded during trading, a decline of 54% from the average daily volume of 1,434,813 shares. The stock had previously closed at $2.48.

Separately, Zacks Investment Research raised shares of Agenus from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Tuesday, August 14th.

The firm has a market capitalization of $289.16 million, a price-to-earnings ratio of -1.88 and a beta of 2.28.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.04). The firm had revenue of $12.80 million for the quarter, compared to the consensus estimate of $10.76 million. As a group, sell-side analysts anticipate that Agenus Inc will post -1.21 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. Jane Street Group LLC acquired a new stake in shares of Agenus during the second quarter worth approximately $101,000. Virtu Financial LLC acquired a new stake in shares of Agenus during the third quarter worth approximately $105,000. Jefferies Group LLC increased its holdings in shares of Agenus by 171.2% during the third quarter. Jefferies Group LLC now owns 166,523 shares of the biotechnology company’s stock worth $356,000 after buying an additional 105,123 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Agenus by 9.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 383,085 shares of the biotechnology company’s stock worth $870,000 after buying an additional 34,065 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Agenus by 26.7% in the third quarter. Wells Fargo & Company MN now owns 941,284 shares of the biotechnology company’s stock valued at $2,015,000 after purchasing an additional 198,247 shares in the last quarter. 31.74% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/agenus-agen-shares-down-6-9/2662959.html.

About Agenus (NASDAQ:AGEN)

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Featured Story: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.